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Drivers of care costs and quality in the last 
3 months of life among older people  
receiving palliative care: A multinational 
mortality follow-back survey across England, 
Ireland and the United States
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Diane E Meier4, Melinda Smith1, Regina McQuillan5, Lucy Selman1,6 ,  
Steven Z Pantilat7, Charles Normand1,2, R Sean Morrison4  
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Abstract
Background: Care costs rise towards the end of life. International comparison of service use, costs and care experiences can inform 
quality and improve access.
Aim: The aim of this study was to compare health and social care costs, quality and their drivers in the last 3 months of life for older 
adults across countries. Null hypothesis: no difference between countries.
Design: Mortality follow-back survey. Costs were calculated from carers’ reported service use and unit costs.
Setting: Palliative care services in England (London), Ireland (Dublin) and the United States (New York, San Francisco).
Participants: Informal carers of decedents who had received palliative care participated in the study.
Results: A total of 767 questionnaires were returned: 245 in England, 282 in Ireland and 240 in the United States. Mean care costs 
per person with cancer/non-cancer were US$37,250/US$37,376 (the United States), US$29,065/US$29,411 (Ireland), US$15,347/
US$16,631 (England) and differed significantly (F = 25.79/14.27, p < 0.000). Cost distributions differed and were most homogeneous 
in England. In all countries, hospital care accounted for > 80% of total care costs; community care 6%–16%, palliative care 1%–15%; 
10% of decedents used ~30% of total care costs. Being a high-cost user was associated with older age (>80 years), facing financial 
difficulties and poor experiences of home care, but not with having cancer or multimorbidity. Palliative care services consistently had 
the highest satisfaction.
Conclusion: Poverty and poor home care drove high costs, suggesting that improving community palliative care may improve care 
value, especially as palliative care expenditure was low. Major diagnostic variables were not cost drivers. Care costs in the United 
States were high and highly variable, suggesting that high-cost low-value care may be prevalent.
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Introduction
Health and social care costs are high in the last 3 months 
of life, yet patients and those close to them often report 
poor experiences.1,2 Much time is spent in hospital, 
despite most people preferring to be at home.3,4 In 
Manitoba, Canada, in the last 6 months of life, decedents 
(who represent 1% of the adult population) generated 
21.3% of the total cost.5 Aldridge and Kelley suggested 
that 13% of the US$1.6 trillion spent on the US health care 
was for individuals in their last year of life; much accounted 
for by a few very high-cost patients.6 A recent analysis of 
Medicare costs suggested the last year of life was ~20% of 
spending, with costs increasing rapidly in the last days of 
life, especially when patients are in hospital.7 Ensuring an 
appropriate balance of treatments with curative and pal-
liative intent and avoiding inappropriate treatments or 
transitions is not only desirable for patients and families8,9 
but also benefits health care policy and expenditure.10–12
Annual numbers of deaths will escalate in many 
countries,13–15 stressing future services.16 Adults over 
65 years of age represent >12% of the population (17.7% in 
England, 12.6% in Ireland and 13% in the United States). 
Most deaths occur in this age group. Variations in national 
policies and palliative and other care entitlements mean that 
international comparisons can inform improving access, care 
quality and cost-effectiveness.17–19 There are no direct 
international comparisons of cost patterns at the end of life 
across different health systems. Cost comparisons rarely con-
sider care quality alongside costs to gauge value (quality/
costs), despite quality being a palliative care cornerstone. To 
fully support informed choices, we need to understand pat-
terns of service use and associated factors, including services 
outside of hospitals, which are often missed.20
Therefore, we aimed to determine and compare across 
three countries, and disease groups focusing on older 
patients with complex needs, who might have higher 
chances of a better experience because of getting in touch 
with the specialist palliative care: (1) patterns of hospital, 
primary and community health service use by older adults 
known to palliative care services; (2) main drivers of vari-
ation in use of services and resultant costs and (3) experi-
ence of bereaved carers with services (as a measure of 
care quality) and its relation to care costs. We tested the a 
priori null hypothesis that there was no difference 
between countries in health and social care costs.
Method
Study design
We conducted a mortality follow-back postal survey of 
key informants (normally relatives and carers) of dece-
dents identified by palliative care services in participating 
What is already known about the topic?
•• Large variation exists in the health service use near the end of life and a 10% of patients are especially high-cost users.
•• A high proportion of care costs in the last year of life occur in the last 3 months.
•• Patients nearing the end of life often prefer to be cared for at home, but habitually spend much time in hospital.
What this paper adds?
•• Our samples are from older patients with higher risks and more complex needs, having had contacts with specialist pal-
liative care services in three countries where palliative care services are established and integrated into the health care 
system.
•• In the last 3 months of life, more than 80% of the total health and social costs were attributable to hospital care and the 
costs of palliative care were only ~10%, despite the fact that all patients had accessed specialist palliative care and 
reported high satisfaction with these services.
•• Uniquely we were able to compare actual costs, based on utilization, therefore providing a more robust comparison 
between countries with different reimbursement systems.
•• Cost distributions in England were more homogeneous, and with lower mean costs, than in both the United States and 
Ireland.
•• Financial difficulties and poor experience with home care services were associated with being a high-cost patient, but 
having cancer or non-cancer, or having multimorbidity was not.
Implications for practice, theory or policy
•• Increasing community palliative care services may help older patients at the end of life avoid unwanted hospital care 
and increase care quality, value and access, and it should be a policy priority.
•• People with poverty, increased age and receiving poor home care should be a target for future interventions to improve 
care at the end of life.
•• The lower and more homogeneous costs in England require investigation, including the effects of different payment/
reimbursement systems for health care.
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hospitals. Reporting follows STROBE21 and MORECARE 
statements.22 See declarations for ethical approvals.
Settings
Three countries included are in the top 10 of the Economist 
Intelligence Unit’s Quality of Death Index; rankings 
(scores) are the following: England – 1 (93.9), Ireland – 4 
(85.8) and the United States – 9 (80.8),23 with differences 
in health care systems (England: National Health Service; 
Ireland: National Health Insurance; the United States: 
Private Health System; palliative care covered by most 
insurance agencies and Medicare and Medicaid.)24 and 
roles of philanthropy supporting hospice and palliative 
care,19 and participating palliative care services in London 
(England), Dublin (Ireland) and New York, San Francisco 
(USA) were the established hospital palliative care con-
sulting teams in all countries, a hospital-based community 
outreach team in London and an inpatient palliative care 
ward in New York. Details of the participating services are 
found elsewhere.25
Inclusion criteria
We identified patients aged ⩾ 65 years who had accessed 
(⩾ 1 contact) a participating palliative care team and died 
4–10 months prior to the survey date. Their next of kin 
(referred to hereafter as ‘carer’), as recorded in clinical 
records, was sent study information and a postal question-
naire from their clinical service (following data-protection 
regulations), with a pre-paid envelope addressed to the 
research team. All data were analysed anonymously.
Questionnaire and data collection
Consenting carers returned a self-report question-
naire,26,27 pre-piloted in all countries. The Client Service 
Receipt Inventory (CSRI)28–30 collected health and social 
care use in the last 3 months of life. This captured the 
detail of service utilization. Carers rated the quality of ser-
vices in different places (e.g. hospital, home) using Likert-
type scales. Health-related quality of life of patients 
3 months and 1 week before death was asked using stand-
ard five items in EQ-5D-3L.31,32 Carers reported demo-
graphic data, including socio-economic status, clinical and 
living arrangements. This was supplemented by patient 
record data on age, diagnosis and co-morbidities.
Analysis
We analysed demographic and clinical data for each country 
and compared age and place of death with population-
based national statistics. We could not compare the charac-
teristics of responders and non-responders due to ethical 
and data-protection constraints. We converted five EQ-5D 
dimensions (mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression) into an index score using 
English population values,33 which ranged from −0.594 to 1.
To determine the care costs for each patient, we mul-
tiplied the quantity of specific services used according 
to the CSRI with corresponding country-specific unit 
costs.34–36 Where published unit costs were unavailable, 
in Ireland and the United States, we used the World 
Health Organization (WHO)-CHOosing Interventions 
that are Cost-Effective (CHOICE) method,37 which esti-
mates unit cost values for primary and secondary health 
care services. All costs were translated into USD (US$) 
for comparison, using the purchasing power parity (PPP) 
index. To calculate aggregated care costs, we grouped 
services into the following:
•• Hospital = services provided in hospitals (intensive 
care, inpatients and outpatients), emergency room 
visits, ambulance services and day case treatments;
•• Community = services received either in care 
homes or at home;
•• Palliative care = services from a dedicated palliative 
care unit (e.g. within specific units in hospitals or 
inpatient hospices), from specialist palliative care 
teams, dedicated or specialist nurses (e.g. Marie 
Curie, Macmillan or Irish Cancer Society/Irish 
Hospice Foundation nurses; see notes under 
e-Table 4 for roles of these nurses).
We tested our null hypothesis using one-way analysis 
of variance (ANOVA) tests. We analysed the costs for peo-
ple with cancer separately from those with non-cancer 
because of their different access levels to palliative care, 
which also varies internationally and may have influenced 
costs (the Bonferroni correction for multiple compari-
sons). Missing values in service use volume were imputed 
with medians. Sensitivity analyses applied English unit 
costs to service use in all countries, in case differences in 
aggregate costs were due to differences in country unit 
costs, rather than service use.
We plotted the cost distributions for each country. We 
identified individuals in the top 10% care costs, using 
Aldridge and Kelley’s6 approach and conducted logistic 
regression analysis to identify factors associated with 
being a high-cost patient. Regression analyses explored 
the relationship between care costs and carers’ experi-
ence with care, with and without adjustment for co-mor-
bidities. We included explanatory variables based on 
theories and literature. Sensitivity analysis also explored 
factors associated with total costs using regression analy-
sis. We used complete cases only. We imputed missing 
values, assuming missing at random, as a sensitivity analy-
sis to see if this influenced the results.
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Our sample size is based on being able to detect a dif-
ference in the mean care costs between countries, with 
80% of power and α = 0.05 (0.025 with Bonferroni correc-
tion for two pairs of comparison), which would require 
229 individuals in each group. To allow regression analy-
sis, anticipating 25 explanatory variables: 50 + 25 × 8  
= 250.38 Therefore, we aimed to recruit > 750 people and 
to allow country comparison and subgroup analysis > 230 
per country. Allowing for 30% response, as is usual in such 
surveys,39 we approached ~2000 individuals across the 
three countries.
Results
Sample characteristics (deceased patients 
and their bereaved carers)
We received 767 completed surveys: 245 (32.4%) of 756 
delivered surveys in London, 282/580 (48.6%) in Dublin, 
131/548 (23.9%) in New York and 109/342 (31.9%) in San 
Francisco.
Patients’ mean age at death was 80 years; 52.8% were 
women, most were married/had a partner (51%) or wid-
owed (33%) (Table 1). Sample decedents were slightly 
younger than in national populations; the proportion was 
slightly higher for hospital deaths and slightly lower for 
home deaths (e-Tables 1 and 2). In the United States, 
decedents were ethnically more diverse (58% White) than 
in England and Ireland (88%, 99% White). Overall, 49% 
died from cancer; higher in England (60%) than in Ireland 
(48%) and lowest in the United States (39%); 50% of 
patients had ⩾ 2, and 6% ⩾ 6, co-morbidities; data not 
available in Ireland; 4% had been finding it difficult or very 
difficult financially and 10% reported being just about 
alright. As expected in this population, EQ-5D index scores 
were low and fell towards death with no significant differ-
ence between countries. Most responding bereaved car-
ers were spouses/partners (36.3%) or daughters/sons 
(47.7%); 70% were women and average age was 60 years. 
Missing values were infrequent and scattered with no par-
ticular pattern, 2%–5% of variables.
Patterns of hospital, primary and 
community health service in the last 
3 months of life
Almost all patients used hospital services, with 70%–85% 
hospitalized at least once. Over half of the non-cancer 
patients in the United States had an intensive care unit 
(ICU) stay, as did over one-third of cancer patients in 
Ireland and the United States. A general practitioner/
family doctor (GP/FD) was the main health care profes-
sional in community settings, especially in England and 
Ireland. Patients in the United States (36% cancer, 39% 
non-cancer) were far more likely to stay overnight in a 
palliative care unit/inpatient hospice than patients in 
other countries; only 14%–15% of cancer and 2%–3% of 
non-cancer patients had hospice/palliative care unit 
stays in England or Ireland. Cancer patients received 
more palliative care than non-cancer patients in England 
and especially in Ireland (e.g. palliative care team was 
seen by 47% of cancer and 21% of non-cancer patients in 
England; 37% of cancer, 6% of non-cancer patients in 
Ireland) (e-Table 4).
Health and social care costs in the last 
3 months of life
Cost distributions were positively skewed; median costs 
were lower than mean costs (Figure 1). In England costs 
were more homogeneous, many patients had low per-
user cost. In the United States and Ireland, more patients, 
especially with non-cancer, had higher cost. Mean per-
patient costs were lowest in England; the United States 
had more than double English care costs. Results were 
similar in the sensitivity analyses using the same unit costs 
for all countries. Hospital costs were 79%–88% of total 
care cost (Table 2, e-Table 5).
Of total care costs, community care costs were 9(16)%, 
5(8)% and 9(11)% in England, Ireland and the United 
States in cancer(non-cancer), respectively. In cancer 
patients, palliative care comprised 5% (US$775), 13% 
(US$4444) and 8% (US$3058) of costs in England, Ireland 
and the United States, respectively (e-Table 5, e-Figure 1).
Main drivers of variation in use of services 
and resultant costs
Across the three countries, the mean total costs were 
US$76,919 per patient in the highest 10% and US$19,865 
in the rest (Table 3): a small number – 25, 28 and 25 
patients – used 29%, 30% and 34% of the total costs in 
England, Ireland and the United States, respectively. 
These highest cost patients (10%) spent 3.9-fold the total 
costs and 4.3-fold the hospital costs of the remaining 90%.
Being aged > 80 years (β = 0.07, 95% CI 0.03– 0.10) 
and experiencing financial difficulty (β = 1.92, 95% CI 
0.42–3.41) were significantly associated with being in the 
highest 10% in all countries. When we included the num-
ber of co-morbidities in the model, age and financial dif-
ficulties remained associated with being a high-cost user. 
The number of co-morbidities was not associated with 
care costs (e-Table 6).
Bereaved carer’s experience of services and 
relationship to care cost
Bereaved carers rated the services provided to patients as 
‘good’ or ‘better’, except at care homes in the United States 
which were rated lower, as ‘fair’ to ‘good’. Consistently, 
Yi et al. 5










 Husband/wife or partner 34.3% 33.1% 41.8% 36.3%
 Son or daughter 47.1% 53.8% 41.4% 47.7%
 Brother or sister 3.7% 5.5% 3.4% 4.2%
 Other relative 7.4% 6.2% 7.6% 7.0%
 Friend or neighbour 6.2% 0.7% 5.5% 4.0%
 Staff in care home 1.2% 0.0% 0.4% 0.5%
 Other official 0.0% 0.7% 0.0% 0.3%
Women (n = 749) 72.6% 67.9% 70.9% 70.4%
Age (years; n = 738) 61.6(12.6) 59.2(13.7) 60.9(14.1) 60.5(13.5)
Ethnicity (= 1 if White; n = 725) 85.2% 100.0% 59.3% 82.5%
Employment status (n = 730)
 Employed and paid 35.3% 43.6% 52.4% 43.7%
 Employed and unpaid 8.5% 13.6% 8.7% 10.4%
 Unemployed 8.9% 9.1% 6.5% 8.2%
 Retired 47.2% 33.7% 32.5% 37.7%
Religion (= 1 if religious; n = 729) 82.6% 92.6% 79.9% 85.5%
Patient
Women 54.3% 51.4% 52.9% 52.8%
Age (years; n = 766) 79.7(8.3) 80.8(8.2) 78.5(9.1) 79.7(8.6)
 65–69 13.9% 12.8% 21.7% 15.9%
 70–79 36.3% 29.9% 32.9% 32.9%
 80–89 36.3% 41.6% 33.3% 37.3%
 90–102 13.5% 15.7% 12.1% 13.8%
Marital status (n = 737)
 Never married 9.4% 7.5% 6.4% 7.7%
 Widowed 33.2% 41.6% 23.8% 33.2%
 Married/civil partnership 48.5% 49.4% 56.2% 51.3%
 Divorced/separated 8.9% 1.5% 13.6% 7.7%
Ethnicity (= 1 if White; n = 723) 88.0% 99.2% 57.5% 82.4%
Diagnosis (n = 763)
 Lung and respiratory cancer 13.5% 11.4% 7.9% 11.0%
 Breast cancer 2.0% 3.9% 2.9% 3.0%
 Genitourinary cancer 12.7% 7.5% 5.8% 8.6%
 Lymphatic cancer 10.2% 5.7% 5.8% 7.2%
 Digestive cancer 12.2% 10.3% 12.1% 11.5%
 Ill-defined cancer 6.1% 3.9% 0% 3.4%
 Other cancer 2.9% 5.0% 4.2% 4.0%
 Non-cancer respiratory 7.4% 16.0% 9.2% 11.1%
 Non-cancer circulatory 14.7% 16.7% 26.3% 19.0%
 Non-cancer CNS 10.2% 7.1% 2.9% 6.8%
 Renal failure 1.2% 3.2% 6.7% 3.7%
 Other non-cancer 5.7% 9.2% 16.3% 10.3%
Total cancer (= 1 if any cancer) 60.3% 47.7% 38.7% 48.9%
Primary carer (= 1 if available; n = 731) 87.6% 87.1% 92.2% 88.8%
Living with (= 1 if with someone else; n = 746) 61.4% 67.9% 75.2% 68.1%
Charlson co-morbidity indexa
 0 25.3% N/Ab 17.9% 21.7%
 1 28.2% 27.9% 28.0%
 2 19.6% 17.1% 18.4%
 3 9.8% 10.4% 10.1%
 4 8.1% 10.4% 9.3%
 5 4.5% 8.8% 6.6%
 >6 4.5% 7.5% 6.0%
 (Continued)
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bereaved carers rated care in hospices/palliative care units 
as the highest (Figure 2, e-Table 7).
Being widowed was associated with poorer reported 
quality of hospital care, whereas being divorced/separated 
was associated with poorer quality of home care. Poorer 
quality of home care was associated with higher hospital 
costs (β = −0.84, 95% CI −1.36 to −0.31); conversely, report-
ing better quality of home care was associated with both 
higher community and palliative care spending (β = 0.69, 
1.34, respectively, e-Table 8). This was consistent when 
adjusting for co-morbidities (e-Table 9).
Discussion
Main findings
This large international study of older people known to pal-









 Living comfortably 48.5% 51.5% 53.6% 51.2%
 Doing alright 39.4% 39.0% 27.4% 35.5%
 Just about getting by 7.9% 5.9% 15.6% 9.6%
 Finding it quite difficult 1.7% 1.8% 1.7% 1.7%
 Finding it very difficult 2.5% 1.5% 1.7% 1.9%
 Don’t know 0.0% 0.4% 0.0% 0.1%
Number of carers (n = 731) 2.5 (1.8) 3.0 (2.0) 2.6 (1.7) 2.7 (1.9)
Religion (= 1 if religious) 88.1% 98.5% 84.6% 90.8%
EQ-5D index scorec
 3 months before death (n = 588) 0.31 (0.42) 0.26 (0.41) 0.41 (0.44) 0.32 (0.43)
 1 week before death (n = 495) −0.20 (0.29) −0.09 (0.37) −0.21 (0.37) −0.16 (0.35)
aDifferent weights were given: 2 for hemiplegia, diabetes with end-organ damages, renal disease, non-metastatic cancer (lymphoma, leukaemia, 
solid tumour) and skin ulcers/cellulitis; 3 for severe liver disease; and 6 for metastatic solid tumour and HIV/AIDS.40
bComorbidity was not collected in participants in Dublin.
cEQ-5D index score was calculated from five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and converted 
into an index score using English population values,32 range is from −0.594 to 1.
Table 1. (continued)
Figure 1. Distribution of hospital care costs in the last 3 months of life for older patients who had access to specialist palliative care 
in England, Ireland and the United States.
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hospital care accounts for over 80% of total health and 
social care costs. Community and palliative care costs were 
low, ranging 6%–16% and 1%–15%, respectively. Care costs 
differed between countries, being the lowest and most 
homogeneous in England. The 10% highest cost patients 
accrued four times the care costs of the remaining 90%. 
Being aged ⩾ 80 years and having difficulty living on current 
income (indicating poverty) were significantly associated 
with higher total costs across all three countries. Clinical fac-
tors were not or only marginally influential. Care quality was 
highest in palliative care unit/inpatient hospices. Poor home 
care was associated with higher hospital costs.
Table 2. Hospital and total health and social care costs in the three countries.
Hospital care 
cost (Unit: US$)
Total care cost 
(Unit: US$)
Percentage of total care cost 
spent on hospital care (%)
England Cancer 13,206 15,347a 86
Non-cancer 13,844 16,631b 83
Ireland Cancer 22,851 29,065a 79
Non-cancer 25,898 29,411b 88
The United States Cancer 30,684 37,250a 82
Non-cancer 31,691 37,376b 85
ANOVA: analysis of variance.
Hospital care was defined as the services provided in hospitals (intensive care units, inpatients and outpatients), emergency room visits, ambulance 
services and day case treatments. Costs were calculated by combining the service use in the Client Service Receipt Inventory with country-specific 
unit costs. All costs were translated into the United States dollar using purchasing power parity index. ANOVA test with Bonferroni correction on 
total formal care costs: afor cancer patients was F = 25.79, p < 0.000 and bfor non-cancer patients was F = 14.27, p < 0.000.
Table 3. Health and social care costs in the last 3 months of life among older patients.
Mean costs per patient (US$)
  Hospital care Community care Palliative care Total
All 90% 16,055 2613 1196 19,865
  81% 13% 6%  
Highest 10% 68,510 2403 6007 76,919
  89% 3% 8%  
Cancer 90% 15,510 2062 1496 19,068
  81% 11% 8%  
Highest 10% 60,257 1932 10,949 73,139
  82% 3% 15%  
Non-cancer 90% 16,702 3174 881 20,757
  80% 15% 4%  
Highest 10% 75,288 2789 1947 80,024
  94% 3% 2%  
England 90% 10,139 1701 503 12,343
  82% 14% 4%  
Highest 10% 41,790 3477 518 45,784
  91% 8% 1%  
Ireland 90% 16,493 2366 1177 20,036
  82% 12% 6%  
Highest 10% 58,496 1383 8969 68,847
  85% 2% 13%  
The United States 90% 21,617 3805 1923 27,344
  79% 14% 7%  
Highest 10% 118,456 3537 5183 127,176
  93% 3% 4%  
In total, 10% of patients with the highest costs were defined in each country. Across the three countries, the mean total health and social care costs 
were US$76,919 per patient in the highest 10% and US$19,865 in the rest. A small number – 25, 28 and 25 patients – used 29%, 30% and 34% of the 
total health and social care costs in England, Ireland and the United States, respectively.
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Strengths and limitations
Our findings have limitations; at the University of 
California, San Francisco (UCSF; the United States) we 
recruited from a palliative care service limited to inpa-
tients, the Irish sample included a high proportion that 
died in hospital, both potentially inflating hospital costs. 
We focussed on four major cities in these three countries, 
and so our results may not represent the countries as a 
whole. Nonetheless, these cities contain large propor-
tions of each country’s population. Furthermore, our find-
ings are supported by previous research revealing that 
hospitals are the main components of costs of care near 
the end of life.7,41–43 Unit costs are not fully representative 
due to multiple payers and providers in all countries. 
Intensive and critical care beds vary internationally in their 
supply, patterns of admission and/or discharge, as well as, 
interpretation and severity of patients admitted.44,45 We 
need more information on the health infrastructure and 
clinical/policy decision-making to understand how these 
differences affect our findings. The EQ-5D was used 
because it is a standard quality of life measure in health 
economic studies and so our values provide useful con-
text. EQ-5D scores were low, and its limited domains may 
have missed symptom and patient experience differences 
between countries.46
A strength is that we used published information, sup-
plemented by the extrapolated costs using methodology 
adopted by the WHO, making the most of available infor-
mation. Sensitivity analysis using English unit costs con-
firmed that the patterns were driven by differences in 
service use. Future research is needed to improve unit 
cost accuracy. By sampling from those known to palliative 
care services, we were able to focus on decedents who 
were more likely to have high levels of needs and high 
costs, but could not focus on very sick patients who did 
not access palliative care services. Mortality follow-back 
surveys inherently suffer from sample and recollection 
bias. Although our response rate is above average for this 
type of study,4,47 as anticipated it was below 50% in all 
sites. For ethical and data-protection reasons, we could 
not compare responders and non-responders and so 
relied on comparisons with national data, which sug-
gested our sample was reasonably representative.
The sample missed many older patients without car-
egivers; understanding this group requires prospective 
study. Respondents may have inaccurately distinguished 
parts of hospital care (e.g. intensive care) or mistaken out-
reach palliative care services with other community ser-
vices; sometimes palliative care might have been reported 
as community services and vice versa.42 However, as com-
munity service contacts were low, major underestimation 
is unlikely. Linking routinely collected acute hospital and 
community service data could provide more information. 
Carers’ experiences differ from patients’ and are not 
patient outcomes. Nevertheless, carers’ experiences are 
crucial; family views influence patient preferences48 and 
good experiences may reduce carers’ grief and morbidity.4 
Uniquely, we collected data firsthand, using standard pro-
cedures specifically for our objectives, rather than relying 
on secondary data sources as in many international com-
parisons. This enhances the validity of our findings.
What this study adds and implications
In this first comparison of overall care costs at the end of 
life between countries, overall costs for patients in 
England were around half of those in Ireland or the United 
States. These differences were significant, not supporting 
our a priori hypothesis. As these costs are based on utili-
zation combined with country-specific unit costs rather 
than on what individuals pay, our data uniquely provide 
reliable comparisons of what people received, irrespec-
tive of payment methods. When individual patient costs 
were considered, more English patients were at the lower 
range and fewer at the higher range of costs, compared 
with Ireland and the United States. To our knowledge, this 
has never been reported before. Reasons for this appar-
ent ‘standardization’ of provision and costs need investi-
gation. It may relate to the health systems – National 
Health Service (England), National Health Insurance 
(Ireland), Private Health System (the United States). 
Variations in unit costs did not explain this. The cost differ-
ences result from different quantities and intensities of 
services used: more patients used more expensive care 
services in the United States and Ireland than in England. 
The lower quality of home care (and higher quality of hos-
pital care) in the United States might have also driven 
higher hospital costs. We were surprised by the high use 
of ICUs, especially in this population. Between-country 
differences may reflect different definitions and criteria 
for ICU admission.44,45 We found no evidence that higher 
Figure 2. Carer’s ratings of the quality of care received at 
home, in hospitals, care homes and hospices/palliative care 
units separately for England, Ireland and the Unites States.
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ICU use led to higher care quality, but this was not a focus 
of our study.
We were surprised by the low costs of palliative care, 
which included inpatient and a range of community and 
hospital services; < 4% of total cost. This was despite our 
study including only patients who had received some pal-
liative care. Given a major preference for quality of life in 
this age group,25 the high quality of palliative care services 
reported in this study and others,49–51 and growing evi-
dence that palliative care teams lower costs and improve 
experiences in serious illness;52,53 these results are con-
cerning and suggest that greater support for palliative 
care services is needed.
In all countries, we identified a patient group with 
higher costs, with the top 10% accounting for around four 
times that of others; these are important for future tar-
geted support. Low satisfaction of home care was consist-
ently associated with higher hospital costs. Poor home 
support may drive admission to hospital; our findings sup-
port other studies that suggest that feeling ‘unsafe’ at 
home leads to emergency department (ED) attendance,54 
and that skilled and available community services are key 
to ensuring home care.4,55,56 Home palliative care can 
reduce hospital admissions, as well as provide care of bet-
ter quality; strengthened home palliative care may be 
important to improve value (quality/costs).4
Our finding that being over 80 years of age was associ-
ated with higher care cost was unexpected; other studies 
have found that care cost near death is lower for older dece-
dents, this warrants further investigation.3 Co-morbidity did 
not affect costs. This differs from studies of community-
dwelling older people, where multimorbidity was associ-
ated with higher costs.57,58 A recent meta-analysis found 
that the economic benefits of palliative care are greatest in 
the face of increasing multiple morbidity.52 Receiving some 
palliative care, as in our study, may have protected against 
multimorbidity increasing costs, adding further evidence to 
support palliative care referral in this population.
Conclusion
In this first major study to compare costs and experiences of 
people in different countries near the end of life, we found 
that care costs are high, hospital care comprises > 80% of 
care costs, and palliative and community care use is low, 
despite patients receiving some palliative care. These novel 
findings suggest that improving palliative care access and 
intensity is an essential priority for health care policy, espe-
cially for non-cancer patients who had least access. Cost dis-
tributions in England were more homogeneous and with 
lower mean costs than in the United States/Ireland, which 
warrants further investigation. Poverty, increased age and 
poor home care were drivers of high costs and should be a 
target for future interventions to improve care quality and 
value at the end of life.
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